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Abstract: Worldwide, colorectal cancer (CRC) is the fourth most commonly diagnosed 
malignant disease and the second leading cause of cancer-related death in Western nations. In 
2008 there were an estimated 148,810 new cases and 49,960 deaths in the US. For several years 
different chemotherapeutic regimens, based on ﬂ  uoropyrimidines, irinotecan and oxaliplatin, have 
been used in advanced CRC, but survival is still unsatisfactory. New targeted therapies, including 
drugs and monoclonal antibodies (MoABs ), show great promise in the ﬁ  ght against CRC and 
have shown activity in different disease settings. Cetuximab, a chimeric IgG1 monoclonal 
antibody that binds to the extracellular domain of epidermal growth factor receptor (EGFR), 
is active in metastatic colorectal cancer (mCRC). As an IgG1 antibody, cetuximab may exert 
its antitumor efﬁ  cacy through both EGFR antagonism and antibody-dependent cell-mediated 
cytotoxicity. The combination of this drug with classical chemotherapies has shown better clini-
cal proﬁ  les reﬂ  ected in an improvement in overall and progression-free survival. Clinical trials 
established the role of cetuximab, particularly with irinotecan, in irinotecan-refractory/heavily 
pretreated patients. Whereas cetuximab has a clear indication in the salvage setting, its role 
in ﬁ  rst-line therapy remains investigational. It is particularly encouraging that cetuximab may 
enhance curative opportunities in patients with early metastatic disease, suggesting that adding 
cetuximab in ﬁ  rst-line therapy may downstage disease in some patients, and, as a result, allow 
potentially curative resection of previously unresectable metastases. In this review we will focus 
on the main epidermal growth factor receptor inhibitors demonstrating clinical beneﬁ  t, and the 
role of cetuximab in ﬁ  rst-line treatment of metastatic CRC.
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Introduction
In Europe, colorectal cancer (CRC) was estimated to be the second most frequent cause 
of cancer-related death in 2006.1 Although there have been substantial advances in 
the treatment of metastatic CRC (mCRC), median survival remains less than 2 years 
and less than 5% of patients survive for more than 5 years.2,3,4,5,6,7
Chemotherapy (CT) is the mainstay of the treatment of mCRC, and, except for 
a minority of patients who are candidates for salvage surgery, in most cases its goal 
is palliation. The standard chemotherapy for patients with advanced CRC (ACC) 
consists of ﬂ  uoropyrimidines, irinotecan and oxaliplatin.8 Since the introduction 
of 5-ﬂ  uorouracil (5-FU), CT has proved to prolong median survival time (MST) of 
patients with advanced disease. With optimal scheduling, 5-FU doubled MST compared 
with best supportive care alone.9,10 Recent advances in combination CT, by addition 
of either oxaliplatin or irinotecan to 5-FU, resulted in improvement in both response 
rate (RR) and overall survival (OS),11 with maximal beneﬁ  t obtained when patients 
receive all three agents during the course of their disease.12 Moreover, combination 
CT has improved the possibility of downstaging metastatic patients, thereby making 
resectable an additional 12% to 20% of patients initially considered unresectable.13 
When these drugs are made available to patients during the course of their disease, 
a median survival of 17 to 20 months may be achieved.OncoTargets and Therapy 2009:2 74
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The treatment of ACC has made considerable progress 
in recent years. The newest developments are monoclonal 
antibodies (MoABs ) such as cetuximab, which have shown 
activity in different disease settings.14,15 The epidermal 
growth factor receptor (EGFR) is a 170-kDa transmembrane 
glycoprotein, which is a member of the ErbB family of 
receptors. Ten different ligands can selectively bind to each 
receptor. After a ligand binds to a single-chain EGFR, the recep-
tor forms a dimer16 that signals within the cell by activating 
receptor autophosphorylation through tyrosine kinase activity.17 
Autophosphorylation triggers a series of intracellular pathways 
that may result in cancer cell proliferation, differentiation, 
migration, and adhesion, and enhances critical tumor growth 
and progression, including angiogenesis, apoptosis inhibition, 
tumor invasiveness, and metastatic spread (Figure 1).
Mechanisms of action of anti-EGFR 
drugs in cancer cells
The ﬁ  rst anti-EGFR drugs were been developed in the 1980s.18 
Anti-EGFR monoclonal antibodies such as cetuximab 
bind to the EGFR extracellular domain during the inactive 
conﬁ  guration. The occlusion of the ligand-binding region pre-
vents the interaction between the receptor and the ligand, ini-
biting ligand-induced EGFR tyrosine kinase activation.19,20
Cetuximab, an IgG1 monoclonal antibody, speciﬁ  cally 
targets EGFR with a higher afﬁ  nity than its natural ligands.21 
Cetuximab prevents EGFR from binding to these endogenous 
ligands and therefore from adopting the extended conﬁ  gura-
tion necessary for dimerization and signal transduction.22 
Monoclonal antibody binding also stimulates receptor internal-
ization and degradation.23,24 In preclinical models, cetuximab 
has been shown to increase tumor cell apoptosis,25,26 suppress 
invasion and metastasis,27 inhibit proliferation,28 and downreg-
ulate the production of proangiogenic factors (Figure 2).29
Additional improvements in treatment are likely to be 
facilitated by the use of rationally selected therapeutic agents 
that target functionally important proteins in tumor cells, such 
as EGFR, expressed in 75% to 89% of CRCs.30,31 EGFR is 
often overexpressed in CRC and EGFR expression levels 
have been shown to be related to prognosis: higher EGFR 
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Figure 1 Signal transduction pathways controlled by the activation of EGFR.
a) The binding of a receptor-speciﬁ  c ligand occurs in the extracellular portion or of one of the EGFR-related receptors (HER2, HER3, HER4). b) The information of a functionally 
active EGFR-EGFR dimer causes the ATP-dependent phosphorylation of speciﬁ  c tyrosine residues in the EGFR intracellular domain. c) This phosphorylation triggers a complex 
program of intracellular signals to the cytoplasm and then to the nucleus to activate a cascade of anti-apoptotic and pro-survival signals.OncoTargets and Therapy 2009:2 75
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expression levels correlating with a shorter OS and greater 
metastatic potential.32
Cetuximab in ﬁ  rst-line treatment 
of metastatic colorectal cancer
Preclinical cancer models
Experimental and clinical studies support the hipotesis that the 
EGFR represents a relevant target for cancer therapy.16 The 
possibility of combining conventional cytotoxic drugs with 
novel agents that speciﬁ  cally interfere with key pathways in 
controlling cancer cell survival, proliferation, invasion and/or 
metastatic spreading has generated a wide interest. Since the 
cellular targets of new agents are different from those of cyto-
toxic drugs, it is possible to combine them with standard chemo-
therapy without the risk of cross-resistance. The modiﬁ  cation of 
the expression and/or the activity of genes regulating mitogenic 
signals can directly cause a perturbation of cell growth, but can 
also affect cancer cell sensitivity to conventional chemotherapy 
and radiotherapy. The EGFR autocrine pathway is one of the 
most active growth factor-driven mechanisms implied in the 
development and in the progression of human epithelial can-
cers. For this reason, in the past few years several preclinical and 
clinical studies have been conducted to test the antitumor activ-
ity of selective EGFR antagonists and cytotoxic therapies.
Morelli et al33 demonstrated, through an in vitro 
model of human cancer epithelial cell line with a func-
tional EGFR-dependent autocrine growth pathway, that 
antiproliferative activity potentiation of selected cytotoxic 
drugs (such as platinum derivatives and taxanes) combined with 
EGFR inhibitors was both schedule- and sequence-dependent. 
This model clearly demostrated how a synergistic effect in 
inhibiting cancer growth could be observed only in those 
neoplastic cells ﬁ  rst exposed to a cytotoxic drug and then 
treated with an EGFR inhibitor. Moreover, cancer cells death 
was signiﬁ  cantly increased and the surviving cells tended to 
accumulate in G2/M phases, showing a modiﬁ  cation in cell 
cycle distribution.
Many preclinical studies have been done to understand the 
mechanisms through which cetuximab succeeds in enhancing 
oxaliplatin’s antiproliferative effect. In the Balin-Gauthier 
et al34 study, the interaction between cetuximab and 
oxaliplatin antitumoral activities was tested on a panel of 
human CRC cell lines (HCT-8, HT-29, SW620, HCT-116). 
It was shown that observed responses were strictly depen-
dent on cell type and on phospho-EGFR basal level, without 
any signiﬁ  cant correlation with EGFR expression level. 
Cetuximab was also proven to lower oxaliplatin IC50 values 
when tested, in vitro, with HCT-8 (EGF-R moderate) and 
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Figure 2 Monoclonal antibody cetuximab blocks EGFR. The anti-EGFR monoclonal antibody cetuximab, which is an IgG1 immunoglobulin, could elicit host antitumor immune 
responses, including antibody-dependent, cell-mediated cytotoxicity and can induce EGFR cellular internalization and downregulation, thereby enhancing receptor degradation. 
These two mechanisms could make an important contribution to antitumor activity.OncoTargets and Therapy 2009:2 76
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HT-29 (EGF-R weak) cell lines, while no major modiﬁ  cation 
was found with HCT-116 or SW620.
In a recent study Balin-Gauthier et al35 used responsive 
(HCT-8) and non-responsive (HCT-116) human colon 
cancer cell lines to analyze the effect of cetuximab on 
oxaliplatin intracellular detoxification, DNA adduct 
formation, cell cycle distribution, and induction of 
apoptosis. In responsive HCT-8 CRC cell line, cetuximab 
induces platinum–DNA adducts formation. This promotion 
is associated with a decreased expression of ERCC1 enzyme 
(excision repair cross complementation group 1) that seems 
to have a key role in the oxaliplatin–DNA platinum adduct 
repair process, the nucleotide excision repair (NER). They 
also observed a reduced expression of factors involved 
in DNA replication initiation, which correlates with an 
enrichment of G1 phase cells, and the stimulation of 
apoptosis pathway with an acceleration of cells death. None 
of these changes occurred in the non-responsive HCT-116 
cell line, showing multiple interactions between oxaliplatin 
pharmacology and the EGFR signaling transduction 
pathway. These results suggested that under oxaliplatin 
treatment, the presence of adducts prevents cells from 
repliction, decreasing the number of S phase cells. On 
the other hand, cetuximab combination therapy modiﬁ  ed 
oxaliplatin adduct repair and induced modiﬁ  cations in the 
early stages of HCT-8 DNA.
Further studies by Prewett et al36 investigated the effects 
of cetuximab and oxaliplatin treatment, single-agent or in 
combination, in vitro and in vivo, by using human CRC 
cell lines selected for oxaliplatin resistance, as well as 
parental control cell lines. Subcutaneous xenograft tumor 
growth in nu/nu athymic mice was evaluated, as well as 
activation of mitogen-activated protein kinase (extracellular 
signal-regulated kinase 1/2) and AKT, expression of 
DNA repair genes, density of apurinic/apyrimidinic DNA 
damage, and accumulation of platinum-DNA adducts in 
vitro. Oxaliplatin and cetuximab combination efﬁ  cacy in 
murine subcutaneous xenograft models was greater than the 
respective monotherapy activity without any correlation with 
oxaliplatin monotherapy responsiveness. In vitro, cetuximab 
reduced expression of excision repair cross-complementation 
group 1 and XPF, which are key components of the nucleotide 
excision repair pathway involved in the cutting of platinum-
DNA adducts. In addition, cetuximab reduced expression of 
XRCC1, a component of the base excision repair pathway 
responsible for repairing apurinic/apyrimidinic sites. Effects 
of cetuximab on DNA reparation proteins were downstream 
to the effects on mitogen-activated protein kinase and AKT 
pathway activation. In line with effects on DNA repair 
protein expression, cetuximab increased the accumulation 
of platinum and apurinic/apyrimidinic sites on DNA during 
oxaliplatin treatment.
In summary, these preclinical studies illustrate cetuximab 
activity in the restoration of chemosensitivity to cytotoxic 
agents and provide a rationale for the evaluation of a 
potentially synergistic sequence of cytotoxic drugs and EGFR 
inhibitors in a clinical setting.
Clinical application
Building upon the effectiveness of cetuximab in refractory 
mCRC, several studies were conduced to explore whether 
adding cetuximab to ﬁ  rst-line therapy would improve patients 
outcome.
A single-arm phase Ib/II study was conducted by Arnold 
et al37 in order to investigate the feasibility of administering 
cetuximab in combination with oxaliplatin and infusional 
5-ﬂ  uorouracil (5-FU)/folinic acid (FA) in a weekly schedule 
(Association of Internal Oncology FUFOX protocol) as 
ﬁ  rst-line treatment in patients with EGFR-positive advanced 
CRC. Cetuximab was administered weekly: 400 mg/m2 initial 
dose, then 250 mg/m2, and FUFOX: oxaliplatin 50 mg/m2, 
FA 500 mg/m2 and 5-FU as a 24-h infusion at either 1500 
or 2000 mg/m2 administered for 4 weeks followed by a 
1-week rest (one cycle). Dose-limiting toxicity (grade 3 
diarrhea) occurred in 3 of 14 assessabled patients receiving 
5-FU at standard 2000 mg/m2. Cetuximab combined with 
FUFOX was generally well tolerated with the most common 
adverse events being diarrhea (27%) and paresthesia (16%) 
grade 3/4. The conﬁ  rmed response rate in patients receiving 
5-FU at standard 2000 mg/m2 (N = 41) was 56%, with a 
median response time of 9.3 months. Median progression-
free survival (PFS) and OS were, respectively, 8.1 (95% 
conﬁ  dence interval [CI] 6.0–9.7) and 28.2 months, including 
all 49 patients. Cetuximab pharmacokinetics did not seem to 
differ in the FUFOX combination compared with cetuximab/
irinotecan combinations.
The ACROBAT study, investigating cetuximab 
combined with FOLFOX-4 in 43 previously untreated ACC 
patients, reported similar grade 3–4 AEs, with diarrhea in 
26% and paresthesia in 19% of patients, but a higher rate of 
neutropenia (23%, probably due to 5-FU bolus administration 
in FOLFOX-4 regimen) and rash (16%). The results showed 
a 77% RR, a median survival of 30 months and a median 
PFS of 12.3 months. Twenty-three percent of these patients 
had their liver metastases resected subsequently.38 The 
favorable results of the ACROBAT trial are due merely OncoTargets and Therapy 2009:2 77
Cetuximab and CRC patients
to selection of patients with favorable prognostic factors 
for cetuximab-based combination chemotherapy. In addition 
to clinical factors (eg, smaller metastases load), this could be 
related to molecular prognostic or predictive factors.
The study of Rosemberg et al in 200239 was designed 
as a phase II study enrolling 27 EGFR-positive patients 
treated with irinotecan, 5-fluorouracil/leucovorin (IFL) 
and cetuximab as frontline. The data showed a 44% partial 
response (PR) rate with a 20% of patients showing minor 
responses. Rash occurred in 26 out of 27 patients, but only 
19% were grade 3.
A similar chemotherapeutic regimen was used in the 
study of Folprecht et al40 in 2005, in which 21 patients with 
EGFR-expressing mCRC underwent cetuximab treatment in 
combination with weekly irinotecan and a low or high dose 
of infusional 5-FU. Among recruited patients 67% obtained 
a RR, 29% stable disease and in 20% of the cases liver 
metastases were resected after treatment. High and normal 
doses of 5-ﬂ  uorouracil/leucovorin were used: in the group of 
high dose (2000 mg/m2) 3 out of 15 patients presented dose 
limiting toxicities (DLT). Median survival was 33 months, and 
4 patients (19%) underwent potentially curative surgery.
A relevant phase II study conducted by Tabernero 
et al41 investigated the efﬁ  cacy and the safety of cetuximab 
combined with standard oxaliplatin-based chemotherapy 
(infusional fluorouracil, leucovorin, and oxaliplatin 
[FOLFOX-4]) in the ﬁ  rst-line treatment of EGFR–expressing 
mCRC. Patients with mCRC received on day 1 of a 14-day 
cycle, cetuximab (initial dose 400 mg/m2 during week 1, then 
250 mg/m2 weekly) followed by FOLFOX-4 (oxaliplatin 
85 mg/m2 on day 1; leucovorin 200 mg/m2 on days 1 and 2, 
followed by ﬂ  uorouracil 400 mg/m2 bolus then 600 mg/m2 
intravenous infusion during 22 hours on days 1 and 2).
The preclinical studies conﬁ  rmed the supra-additive 
activity of cetuximab to oxaliplatin. In the clinical phase, 
43 patients were included, with a median age of 65 years 
(range, 43 to 78 years). RRs were 79% (unconﬁ  rmed) and 
72% (conﬁ  rmed), with 95% of disease control. Median PFS 
(mPFS) and median duration of response were respectively 
12.3 and 10.8 months. Ten patients (23%) with previously 
unresectable metastases underwent curative resection. After 
a median follow-up of 30.5 months, median OS (mOS) was 
30.0 months. Cetuximab did not increase FOLFOX-4 char-
acteristic toxicity and it was generally well tolerated.
A further study with FOLFOX-6 plus cetuximab in chemo-
naïve patients showed a preliminary 53% overall RR (ORR) 
with 3 CR.42 This was a phase II study with 82 mCRC with 
positive or undetectable EGFR expression. Fourteen patients 
left the study due to toxicity and 10% of the patients had 
grade 4 neutropenia and 2% grade 4 sepsis (Table 1).
The CALGB 80203 study was designed to compare 
ﬁ  rst-line FOLFIRI vs FOLFOX, both with and without 
cetuximab. The study was closed to accrual after a total 
of 238 of the planned 2,200 patients were enrolled.43 
Preliminary results showed that response rates were higher 
in the cetuximab arms, especially when administered with 
FOLFOX: 60% for FOLFOX plus cetuximab; 40% for 
FOLFOX alone; 44% for FOLFIRI plus cetuximab; and 36% 
for FOLFIRI alone. Overall, adding cetuximab signiﬁ  cantly 
increased RRs compared to treatment without cetuximab 
(52% vs 38%; p = 0.0029).
A more recent phase III clinical trial, the CRYSTAL 
study, enrolled a total of 1220 patients with untreated 
EGFR-expressing mCRC and randomly assigned them 
to cetuximab plus FOLFIRI (arm A ) or FOLFIRI 
alone (arm B) treatment. Median PFS was significantly 
longer for arm A compared to arm B (8.9 months [CI: 8–9.5] 
for group A vs 8 months [CI: 7.6–9] for group B, P = 0.036). 
RR was also signiﬁ  cantly increased by cetuximab (46.9% vs 
38.7%, p = 0.005) compared to FOLFIRI alone.44 The most 
common toxicities were neutropenia (26.7% in group A, 
23.3% in group B), diarrhea (15.2% and 10.5% respectively) 
and skin reactions (18.7% and 0.2% respectively). The ben-
eﬁ  t derived by patients with liver disease only is particularly 
interesting: the resectability rates of RO (radical resection) 
increased 3-fold with the addition of cetuximab. These 
ﬁ  ndings suggest that cetuximab is active in ﬁ  rst-line setting, 
and especially valuable for patients with synchronous liver 
disease (Table 2).
The OPUS study is a phase III clinical trial45 that 
randomized chemo-naïve patients to FOLFOX or FOLFOX 
plus cetuximab. Their primary end point was response rate 
and secondary goals were PFS, OS, and the R0 resection rate 
after metastatic surgery of curative intent. The preliminary 
results showed an RR of 35.7% and 45.6%, respectively, 
with 337 patients enrolled at that time. The most common 
Table 1 Cetuximab in front-line phase II studies
 Cetuximab 
+ FOLFIRI
Cetuximab 
+ FOLFOX-4
Cetuximab 
+ FOLFOX-6
Pts (n) 22 43 82
RR (%) 80 77 53
PFS (months) 10.9 12.3 –
OS (months) – 30 –
Abbreviations: Pts, patients; RR, response rate; PFS, progression-free survival; OS, 
overall survival.OncoTargets and Therapy 2009:2 78
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grade 3–4 adverse events were neutropenia (27.6% in 
A; 31.5% in B), diarrhea (7.1% and 6.0%), leucopenia (7.1% 
and 5.4%) and rash (9.4% in the cetuximab arm only).
The ongoing UK Medical Research Council’s 
COIN phase III trial46 in mCRC is going to randomize 
approximately 2,400 first-line patients, whose EGFR 
status has not been previously estabilished, to one of 
three arms: continuous oxaliplatin and ﬂ  uoropyrimidine 
chemotherapy, continuous chemotherapy plus cetuximab, 
or chemotherapy for 12 weeks followed by its interruption 
and resumption on disease progression. The addition of 
cetuximab to oxaliplatin/ﬂ  uoropyrimidine combinations 
results in increased grade 3–4 toxicities, and gastroin-
testinal (GI), skin rash and lethargy seem to be the most 
represented.
The results of these ongoing studies will elucidate the 
role of these combination in ﬁ  rst-line treatment.
Cetuximab in combination 
with other novel agents
Animal models suggest that additive efﬁ  cacy and sometimes 
synergy can be achieved using EGFR inhibitors in 
combination with agents that inhibit the vascular endothelial 
growth factor receptor.47,48 The EGFR pathway rules the 
production of vascular endothelial growth factor (and other 
angiogenic factors); targeting both markers may therefore 
have a greater antitumor effect.
The addition of bevacizumab (a humanized mAb against the 
vascular endothelial growth factor) to ﬂ  uoropyrimidine-containing 
chemotherapy49 results in a signiﬁ  cant survival beneﬁ  t and it 
is currently considered as part of standard ﬁ  rst-line therapy. 
In irinotecan monotherapy-resistant patients, the use of 
cetuximab improves mPFS. Cetuximab monotherapy improves 
the mOS in ACC patients in whom all available standard 
treatments have failed.50 In ACC ﬁ  rst-line treatment, cetuximab 
improves PFS when given in combination with bolus 5-FU 
plus FOLFIRI compared with FOLFIRI alone, although the 
absolute increase in mPFS is modest (8.9 vs 8.0 months). So 
far, limited data are available on the efﬁ  cacy and safety of the 
combination of bevacizumab and anti-EGFR targeted agents in 
ACC. A randomized phase II study comparing bevacizumab, 
cetuximab and irinotecan with bevacizumab and cetuximab in 
irinotecan-resistant patients with ACC (BOND-2) showed an 
acceptable toxicity proﬁ  le in both arms and a median time to 
progression of 7.9 vs 5.6 months.51
The Cancer and Leukemia Group B (CALGB/SWOG 
80405) plans to randomize 2,289 mCRC patients for a ﬁ  rst-
line treatment with chemotherapy (FOLFOX or FOLFIRI) 
plus bevacizumab or cetuximab vs the combination 
of bevacizumab plus cetuximab. Patients and their 
Table 2 Clinical studies of cetuximab in ﬁ  rst-line treatment of EGFR-expressing mCRC
Study Type Phase II Treatment 
(No of patients)
ORR 
(CR + PR) (%)
mTTP 
(months) (%)
mPFS 
(months) (%)
MOS 
(months) (%)
ACROBAT trial Andrè et al38 Cetuximab + Folfox − 4 (43) 77 NR 12.3 30.0
Folprecht et al31 Cetuximab + Irinotecan + 5-FU/FA (21) 67 9.9 NR 33
SAKK Group Borner et al64 Cetuximnab + Xelox (37)
vs Xelox (74)
35.1
54
5.8
7.2
NR
16.5
20.5
Study Type phase III Treatment (no. of patients) ORR 
(CR + PR) (%)
mTTP 
(months) (%)
mPFS 
(months) (%)
MOS 
(months) (%)
OPUS trial (on going)45 Folfox vs
Folfox + Cetuximab (337)
35.7
45.6
Phase III CALGB 8020343 Folﬁ  ri (61)
Folﬁ  ri + Cetuximab (59)
Folfox (60)
Folfox + Cetuximab (58)
36
44
40
60
38
32
30
26
8.4
10.6
9.8
8.2
NR
Phase III COIN trial 
(ongoing)46
Continuous Folfox
Continuous Folfox + Cetuximab
CT for 12 weeks followed by its 
interruption and resumption on PD
NR NR NR NR
Phase III CRYSTAL44 Folﬁ  ri (600) vs
Folﬁ  ri + Cetuximab (602)
38.7
46.9
(p = 0.004)
N.R
8
8.9
(p  0.04)
NR
Abbreviations: CRC, colorectal cancer; ORR, overall response rate; CR, complete response; PR, partial response; mPTT, median time to progression;   mPFS, median 
progression-free survival; mOS, median overall survival; NR, not reported.OncoTargets and Therapy 2009:2 79
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physicians will ﬁ  rst choose either the FOLFOX or FOLFIRI 
chemotherapy regimen and then will be randomized to 
treatment with cetuximab, bevacizumab or both. The primary 
endpoint is OS, with RR, PFS, duration of response, and time 
to progression as secondary endpoints. Additionally, this 
study will explore witch regimen is the most likely to allow 
patients to undergo metastases potentially curative surgery 
after chemotherapy.52
CAIRO2 is a randomized phase III trial, evaluating the 
possibility of adding cetuximab to a regimen of capecitabine, 
oxaliplatin, and bevacizumab in order to improve PFS in 
previously untreated mCRC patient. Secondary end points 
are OS, tumor response, duration of response, quality of 
life, safety and translational research on factors that predict 
the response to treatment. 750 patients will be enrolled. 
Treatment consistes of capecitabine 1000 mg/m2 given orally 
twice daily on days 1–14, oxaliplatin 130 mg/m2 iv on day 1 
and bevacizumab 7.5 mg/kg iv on day 1 (arm A) or the same 
schedule plus cetuximab 400 mg/m2 iv in week 1 of the ﬁ  rst 
treatment cycle and 250 mg/m2 iv weekly thereafter (arm B). 
All cycles are administered every 3 weeks. The study is still 
ongoing, but preliminary results on an interim analysis of 
toxicity show that the incidence of overall grade 3–4 toxicity 
is signiﬁ  cantly higher in arm B compared with arm A (81% vs 
72%, p = 0.03). This difference is fully attributed to cetux-
imab-related skin toxicity. The addition of cetuximab does 
not seem to result in an increase of gastrointestinal toxicity 
or treatment-related mortality.53
Response to anti-EGFR drugs: 
clinical and pathological predictors
Since only a subgroup of patients with cancer have a clinical 
beneﬁ  t from treatment with EGFR inhibitors, there is an 
urgent need for identiﬁ  cation and clinical validation of useful 
criteria in selecting patients for such treatment.
A cetuximab-peculiar toxic effect is a papulopustural skin 
rash, generally on the face and upper torso, which is thought 
to be mechanism- and dose-related.54 Findings suggest that 
there is a correlation between intensity of skin rash, response 
and survival.55 This correlation is particularly striking in a 
subgroup analysis from the IMC 0144 trial reported by Pippas 
et al. In that trial, patients with no skin toxicity presented no 
objective responses and had a median survival of 1.7 months, 
whereas those who experienced grade 3 skin rash had a 20% 
RR and a mOS of almost 1 year.56 This is the ﬁ  rst reported 
observation of a clinical feature that may predict the clinical 
outcome of an antitumor agent. Dose-escalation schedules 
are currently under investigation in order to explore the 
possibility of increasing cetuximab efﬁ  cacy by inducing 
skin rash.
However, the presence and severity of cutaneous toxic 
effects are the most important clinical correlates of the 
efﬁ  cacy of anti-EGFR therapy. The skin effect reﬂ  ects 
the extent of EGFR blockade achieved in the tumor and 
correlates with EGFR saturation and with relevant drug 
concentration within the target.
EGFR expression, determined by immuno-histochemical 
methods, was the ﬁ  rst biomarker investigated as a potential 
predictor of response. However, most studies have failed to 
show any relationship between EGFR expression and the 
clinical activity of anti-EGFR drugs.57 Cetuximab has also 
been shown to have clinical activity in patients with EGFR-
negative CRC.58 Collectively, these data suggest that EGFR 
immuno-histochemical testing is not an optimal method for 
identifying patients who may have a response to anti-EGFR 
drug treatment.
Lievre et al recently reported that tumors with KRAS 
mutation are associated with resistance to cetuximab 
therapy.59 In their study, 11 out 30 patients (37%) responded 
to cetuximab therapy, which was mostly given in combination 
with irinotecan alone (75%) and in a multi-refractory setting 
(80%). KRAS mutation was detected in 13 of the 19 non-
responder patients, but none of the responders was found to 
be positive (p = 0.0003).
KRAS activating mutation, which results in an increase 
in the mitogen-activated protein kinase pathway, is detected 
in approximately 40% to 45% of patients with CRC, and 
its presence seems to be correlated with a worse prognosis. 
KRAS mutations are frequently recorded codons 12 and 13 
of exon 2 and usually eliminate the possibility of a concur-
rent EGFR mutation.
In several studies, KRAS mutations have been associated 
with lack of response to cetuximab in patient with advanced 
chemotherapy-refractory colorectal cancer.60,61 These studies 
suggest that constitutive activation of the KRAS signaling 
pathway could impair the response to anti-EGFR drugs.62
Bokemeyer et al63 evaluated the influence of KRAS 
mutation in patients treated with standard ﬁ  rst-line therapy, 
whether or not associated with cetuximab. Best OR and PFS 
time (IRC evaluation) are linked to KRAS mutation presence. 
KRAS mutations were detected in 42% (99/233) of evaluable 
samples. Their data suggest that the beneﬁ  t from addition of 
cetuximab to standard treatment is higher for the population 
with wild-type KRAS. For patients with KRAS mutations, 
no major beneﬁ  t has been shown from adding cetuximab to 
FOLFOX regimen (Table 3).OncoTargets and Therapy 2009:2 80
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These data suggest the possibility of choosing the most 
suitable treatment (cetuximab vs bevacizumab) based on 
KRAS analysis.
Conclusions
The results from the studies reviewed clearly point out the 
major role played by cetuximab in advanced CRC. Cetuximab 
has been used successfully in patients with refractory mCRC, 
and nowadays its role in the management of this tumor is 
growing. A deﬁ  ned role in the treatment of mCRC was 
established for regimens based on cetuximab plus irinotecan. 
Encouraging activity has also been observed in ﬁ  rst-line treat-
ment in combination with FOLFIRI and FOLFOX. Data from 
phase II trials in metastatic disease seem to indicate better 
results obtained with the addition of cetuximab to standard 
chemotherapy treatments (in particular, to oxaliplatin-
containing regimens). On the basis of available evidence, 
the best interaction seems to be achieved when cetuximab 
is combined with oxaliplatin in ﬁ  rst-line treatment and with 
irinotecan in refractory disease. The reason for these results 
is still unclear, but they suggest that interactions between 
cetuximab and oxaliplatin involve pathways different from 
those between cetuximab and irinotecan. Pending data from 
phase III trials will clarify their role in this setting.
It is also particularly evident that cetuximab may enhance 
the curative opportunities in patients with early metastatic 
disease. The early use of cetuximab combined with cytotoxic 
therapy during a treatment course could perhaps make a 
higher fraction of mCRC fully resectable, as asserted by 
the signiﬁ  cantly higher R0 resection rate reported for the 
cetuximab plus ﬂ  uorouracil, leucovorin, and irinotecan arm 
of the Cetuximab Combined With Irinotecan in First-Line 
Therapy for Metastatic Colorectal Cancer (CRYSTAL) 
study. Although most of the patients (91%) experienced 
grade 3–4 adverse events, the combination of cetuximab and 
FOLFOX-4 was generally well tolerated, and there was no 
evidence to suggest that cetuximab increased the frequency 
or the severity of usual FOLFOX toxicities.
Preliminary evidence suggests that adding cetuximab 
to ﬁ  rst-line therapy may downstage disease in metastatic 
patients, allowing a potentially curative resection of previ-
ously unresectable lesions. The signiﬁ  cant improvement in 
resection rate may increase OS.
Future utilization of cetuximab in mCRC treatment could 
combine the activity of the two different biologic agents: 
cetuximab and bevacizumab. The combination of cetuximab 
and bevacizumab, alone or together with other standard drugs, 
appears tolerable and active, and warrants investigation as 
front-line combination chemotherapy regimens. It is likely 
that some patients may beneﬁ  t more from FOLFOX plus 
bevacizumab, others from FOLFIRI plus cetuximab, and still 
others from different combination of chemotherapy and bio-
logic agents. The key will be to determine predictive factors, 
which will help us to identify the treatment that best suits the 
patient. The observation that KRAS gene mutation is associ-
ated with resistance to cetuximab is a promising ﬁ  rst step.
Table 4 Median progression-free survival (mPFS) and overall response rate (RR) by KRAS mutation status
KRAS status Median PFS (mo) 
Cetuximab + FOLFOX
Median PFS (mo) 
FOLFOX
Overall RR (%) 
Cetuximab + FOLFOX
Overall RR (%) 
FOLFOX
Wild-type 7.7 (n = 61) 7.2 (n = 73) HR: 0.57 p = 0.02 61 (n = 61) 37 (n = 73) p = 0.01
Mutation 5.5 (n = 52) 8.6 (n = 47) HR: 1.83 p = 0.02 33 (n = 52) 49 (n = 47) p = 0.11
Abbreviation: HR, hazard ratio.
Table 3 Clinical studies of cetuximab in combination with other novel agent in ﬁ  rst-line treatment
Study type Treatment Patients MOS (months) (%)
Randomized phase II study 
(BOND-2) Saltz et al51
Cetuximab + Bevacizumab + Irinotecan
vs Cetuximab + Bevacizumab
43
40
14.5
11.4
Randomized phase III study 
(CALGB/ SWOG 80405)52
Folfox/Folﬁ  ri + Bevacizumab or Cetuximab
vs Folfox/ Folﬁ  ri + Bevacizumab + Cetuximab
Plans to randomize 2,289 patients Still ongoing
Randomized phase III study 
(CAIRO2)53
Capecitabine + Oxaliplatin + Bevacizumab
vs Capecitabine + Oxaliplatin + Bevacizumab + 
Cetuximab
Plans to randomize 750 patients Still ongoing
Abbreviation: MOS, median overall survival.OncoTargets and Therapy 2009:2 81
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All these data must encourage clinicians and basic 
researchers to maintain their efforts to untangle the EGFR 
network, in order to improve patient quality of life and 
survival.
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